PHAARMASIA LTD. (PHRMASI) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of PHAARMASIA LTD. stock ₹52.27, price ₹100.47, that is 48.0% below the price, quality 78 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
PHAARMASIA LTD.
PHRMASI · BSEFar too expensive (fair value 48% below the price), but strong company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ₹21.25 – ₹129.20 · fair‑value band ₹39.20 – ₹65.34 · the ₹100.47 price screens above the ₹52.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.
Every Wednesday you see whether PHAARMASIA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India.
Show moreShow less
The company offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections.
It provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
Stock analysis
PHAARMASIA LTD. (PHRMASI) currently trades at ₹100.47, while our model-based Fair Value estimate is ₹52.27, 48% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Earnings-Based group reads highest at a median of ₹400.26 per share, and 7 of the 14 models we run sit above the ₹100.47 price.
Bear case: the Asset-Based group reads lowest at ₹27.50, and 7 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹39.20 (bear) to ₹65.34 (bull), the price of ₹100.47 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 78/100 (high quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
PHAARMASIA LTD. reported revenue of ₹472M in FY2026 versus ₹172M in FY2022, a compound +28.7%/yr. Reported net income was ₹176M in FY2026.
Key figures
Market cap ₹686M (≈ $7.4M) Micro · P/E ratio 3.9 · P/S ratio 1.41 · EPS (TTM) ₹25.85 · Net margin 36.3% · Return on equity 114% · Return on assets (EBIT) −5.1% (5-year average) · Operating margin 3.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 115% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at −48%, PHRMASI screens richer than that median.
Fair Value models
All 14 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
PHRMASI screens overvalued: fair value 48% below the price. Compare with Merck KGaA →
Compare PHAARMASIA LTD. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 611 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $79.11 | $113.53 | +44% | vs PHRMASI |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.00 | ¥51.70 | +10% | vs PHRMASI |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,884.90 | ₹1,982.92 | +5% | vs PHRMASI |
| Haleon plc HLN | $9.07 | $8.47 | −7% | vs PHRMASI |
| Merck KGaA MRK | €146.45 | €108.83 | −26% | vs PHRMASI |
| Galderma Group GALD | CHF 182.85 | CHF 112.84 | −38% | vs PHRMASI |
| Teva Pharmaceutical Industries Limited TEVA | $39.23 | $20.74 | −47% | vs PHRMASI |
| Takeda Pharmaceutical Company TAK | $21.77 | $11.26 | −48% | vs PHRMASI |
| Sandoz Group SDZ | CHF 80.50 | CHF 40.87 | −49% | vs PHRMASI |
| Divi's Laboratories Limited DIVISLAB | ₹11,180.50 | ₹1,566.89 | −86% | vs PHRMASI |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is PHAARMASIA LTD. (PHRMASI) overvalued or undervalued?
What is the fair value of PHRMASI?
What is the quality score of PHRMASI?
What is the price target for PHAARMASIA LTD. (PHRMASI)?
What is the PHAARMASIA LTD. stock forecast for 2026?
What is the revenue of PHAARMASIA LTD. (PHRMASI)?
What is the intrinsic value of PHAARMASIA LTD. (PHRMASI)?
Is PHAARMASIA LTD. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of PHRMASI?
How much is PHAARMASIA LTD. worth?
What do the bullish and bearish scenarios say about PHRMASI?
What is the P/E ratio of PHRMASI?
How solid is the balance sheet of PHAARMASIA LTD. (PHRMASI)?
How far is PHRMASI from its 52-week high?
Which stocks are comparable to PHAARMASIA LTD.?
Is PHAARMASIA LTD. stock attractive at the current price?
How is the fair value of PHRMASI calculated?
Is it still worth investing in stocks now?
What is the share price of PHAARMASIA LTD. (PHRMASI)?
What should I pay attention to with PHAARMASIA LTD. right now?
Key figures of PHAARMASIA LTD.
How large is the market capitalisation of PHAARMASIA LTD. (PHRMASI)?
What is the P/S ratio of PHAARMASIA LTD. (PHRMASI)?
What are the earnings per share of PHAARMASIA LTD. (PHRMASI)?
What is the net margin of PHAARMASIA LTD. (PHRMASI)?
What is the return on equity of PHAARMASIA LTD. (PHRMASI)?
What is the EBIT return on assets of PHAARMASIA LTD. (PHRMASI)?
What is the operating margin of PHAARMASIA LTD. (PHRMASI)?
How fast is revenue growing at PHAARMASIA LTD. (PHRMASI)?
How fast are earnings growing at PHAARMASIA LTD. (PHRMASI)?
How much free cash flow does PHAARMASIA LTD. (PHRMASI) generate?
How much net debt does PHAARMASIA LTD. (PHRMASI) carry?
Watch PHAARMASIA LTD. in the live analysis
One click puts PHAARMASIA LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.